Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Victor

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
American Journal of Diseases of Children (1960)|July 1, 1974
Clinical staging in Reye syndromeF H Lovejoy, A L Smith, M J Bresnan, et al.
Leukemia Research|July 14, 2018
Management of melanoma in patients with chronic lymphocytic leukemiaWilliam J Archibald, Philip J Meacham, AnnaLynn M Williams, et al.
JCO Precision Oncology|February 13, 2026
Multi-Institutional Study Evaluating the Role of Early Circulating Tumor DNA Dynamics During Treatment With Immune Checkpoint Inhibitors in Patients With Advanced-Stage MelanomaVincent T Ma, Alice Y Zhou, Amir Forati, et al.
Journal of Medicinal Chemistry|April 2, 2005
Structure-activity relationships of pregabalin and analogues that target the alpha(2)-delta proteinThomas R Belliotti, Thomas Capiris, I Victor Ekhato, et al.
Journal for Immunotherapy of Cancer|August 12, 2021
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)Michael J Wagner, Megan Othus, Sandip P Patel, et al.
NPJ Precision Oncology|January 24, 2025
Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinomaSandip P Patel, Eleanor Cano-Linson, Young Kwang Chae, et al.
Nature Medicine|August 17, 2023
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trialAri VanderWalde, Shay L Bellasea, Kari L Kendra, et al.
Cancer Discovery|April 21, 2026
Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1Katie M Campbell, Daniel G Chen, Zaid E Bustami, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
American Journal of Diseases of Children (1960)|July 1, 1974
Clinical staging in Reye syndromeF H Lovejoy, A L Smith, M J Bresnan, et al.
Leukemia Research|July 14, 2018
Management of melanoma in patients with chronic lymphocytic leukemiaWilliam J Archibald, Philip J Meacham, AnnaLynn M Williams, et al.
JCO Precision Oncology|February 13, 2026
Multi-Institutional Study Evaluating the Role of Early Circulating Tumor DNA Dynamics During Treatment With Immune Checkpoint Inhibitors in Patients With Advanced-Stage MelanomaVincent T Ma, Alice Y Zhou, Amir Forati, et al.
Journal of Medicinal Chemistry|April 2, 2005
Structure-activity relationships of pregabalin and analogues that target the alpha(2)-delta proteinThomas R Belliotti, Thomas Capiris, I Victor Ekhato, et al.
Journal for Immunotherapy of Cancer|August 12, 2021
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)Michael J Wagner, Megan Othus, Sandip P Patel, et al.
NPJ Precision Oncology|January 24, 2025
Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinomaSandip P Patel, Eleanor Cano-Linson, Young Kwang Chae, et al.
Nature Medicine|August 17, 2023
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trialAri VanderWalde, Shay L Bellasea, Kari L Kendra, et al.
Cancer Discovery|April 21, 2026
Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1Katie M Campbell, Daniel G Chen, Zaid E Bustami, et al.
Pageof 2